Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06648850 | Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth | PHASE2 | NOT YET_RECRUITING | 1,120 | — | — | May 1, 2026 | Apr 26, 2027 | Apr 13, 2026 | - | — |
Number of hairs shedding during brushing at target area
| Arm | Type | Description |
|---|---|---|
| DA-001 Topical | EXPERIMENTAL | Phenylephrine 2.5% Topical + TAAR agonist |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Phenylephrine Topical | EXPERIMENTAL | Phenylephrine 2.5% Topical (per application volume - males 5mL and females 20mL) |
| DA-001 Topical + DA-005 Oral (HIF-1α supplement) | EXPERIMENTAL | DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement) |
| DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement) | EXPERIMENTAL | Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement) |
| Phenylephrine Topical 0.25% + Intact Pro Topical | EXPERIMENTAL | Phenylephrine Topical 0.25% + Intact Pro Topical |
| Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement) | EXPERIMENTAL | Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement) |
| Name | Type | Description |
|---|---|---|
| DA-001 | DRUG | Phenylephrine 2.5% Topical + TAAR Agonist (GRAS) Topical Solution |
| Placebo | OTHER | Placebo Topical Solution |
| Phenylephrine | DRUG | Phenylephrine 2.5% Topical |
| DA-001 Topical + DA-005 Oral (HIF-1α supplement) | OTHER | DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement) |
| DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement) | OTHER | Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement) |
| Phenylephrine Topical 0.25% + Intact Pro Topical | DRUG | Phenylephrine 0.25% + Intact Pro (50% stronger) |
| Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement) | OTHER | Phenylephrine 0.25% + Intact Pro (50% stronger) + DA-005 Oral (HIF-1α supplement) |
Inclusion Criteria: * Age 18 or older * Diagnosed with telogen effluvium * Willing and able to apply the treatment as directed, comply with study * Otherwise healthy * Able to give informed consent Exclusion Criteria: * A medical history that may interfere with study objectives * Women who are pr...